Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

90% of patients achieved high grade disease-free status at any time point with NDV-01, demonstrating strong proof-of-concept for sustained-release “GEM/DOCE” formulation*